Dietmar Trenk

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7422819/publications.pdf

Version: 2024-02-01

40 papers	7,384 citations	201385 27 h-index	288905 40 g-index
40 all docs	40 docs citations	40 times ranked	5404 citing authors

#	Article	IF	Citations
1	Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. Journal of the American College of Cardiology, 2010, 56, 919-933.	1.2	1,058
2	Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI. JAMA - Journal of the American Medical Association, 2010, 304, 1821.	3.8	980
3	Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention. Circulation, 2007, 116, 2923-2932.	1.6	831
4	A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents. Journal of the American College of Cardiology, 2012, 59, 2159-2164.	1.2	569
5	Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement. Journal of the American College of Cardiology, 2006, 48, 1742-1750.	1.2	558
6	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2019, 381, 1524-1534.	13.9	543
7	Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents. Journal of the American College of Cardiology, 2008, 51, 1925-1934.	1.2	523
8	Updated Expert Consensus Statement on Platelet Function and Genetic Testing forÂGuiding P2Y12 Receptor Inhibitor Treatment in Percutaneous CoronaryÂIntervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	1.1	366
9	Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention. Circulation, 2005, 111, 2560-2564.	1.6	363
10	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptorâ€“Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
11	Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent Placement. Journal of the American College of Cardiology, 2010, 55, 2427-2434.	1.2	285
12	Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. International Journal of Cardiology, 2013, 167, 2140-2148.	0.8	113
13	Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement. Circulation: Cardiovascular Genetics, 2011, 4, 429-436.	5.1	91
14	Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 203-210.	1.4	69
15	The Duration of the Amplified Sinus-P-Wave Identifies Presence of LeftÂAtrial Low Voltage Substrate and Predicts Outcome After Pulmonary VeinÂIsolation in Patients With PersistentÂAtrial Fibrillation. JACC: Clinical Electrophysiology, 2018, 4, 531-543.	1.3	67
16	Comparison of Immature Platelet Count toÂEstablished Predictors of PlateletÂReactivity During ThienopyridineÂTherapy. Journal of the American College of Cardiology, 2016, 68, 286-293.	1.2	57
17	Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thrombosis and Haemostasis, 2008, 99, 174-181.	1.8	52
18	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. European Heart Journal, 2020, 41, 3132-3140.	1.0	52

#	Article	IF	Citations
19	Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes. Annals of Internal Medicine, 2020, 173, 436-444.	2.0	44
20	How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors â€“ is an algorithm the answer?. Thrombosis and Haemostasis, 2015, 113, 37-52.	1.8	43
21	Ticagrelor or Prasugrel in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2020, 76, 2436-2446.	1.2	41
22	Genetics of platelet inhibitor treatment. British Journal of Clinical Pharmacology, 2014, 77, 642-653.	1.1	37
23	Ultrastructural, transcriptional, and functional differences between human reticulated and nonâ€reticulated platelets. Journal of Thrombosis and Haemostasis, 2020, 18, 2034-2046.	1.9	34
24	Identification of 5-HT3 receptors on human platelets: Increased surface immunoreactivity after activation with adenosine diphosphate (ADP) and thrombin receptor-activating peptide (TRAP). Thrombosis and Haemostasis, 2008, 99, 784-786.	1.8	33
25	Impact of On-Clopidogrel Platelet Reactivity on Incidence of Hypoattenuated Leaflet Thickening After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 12-18.	1.1	32
26	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Clinical Pharmacology and Therapeutics, 2020, 108, 1067-1077.	2.3	32
27	How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors â€“ is an algorithm the answer?. Thrombosis and Haemostasis, 2015, 113, 37-52.	1.8	31
28	High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials. Thrombosis and Haemostasis, 2013, 109, 834-845.	1.8	28
29	Ticagrelor or Prasugrel in Patients With ST-Segmentâ€“Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation, 2020, 142, 2329-2337.	1.6	26
30	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end pointsâ€”Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). American Heart Journal, 2018, 198, 152-159.	1.2	24
31	Randomized Comparison of Different Thienopyridine Loading Strategies in Patients Undergoing Elective Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 219-227.	1.1	23
32	Impact of reticulated platelets on antiplatelet response to thienopyridines is independent of platelet turnover. Thrombosis and Haemostasis, 2016, 116, 941-948.	1.8	21
33	Evaluation of an Alternative Staining Method Using SYTO 13 to Determine Reticulated Platelets. Thrombosis and Haemostasis, 2019, 119, 779-785.	1.8	18
34	Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: Platelet reactivity in an observational study. Platelets, 2013, 24, 549-553.	1.1	16
35	Echocardiographic diagnosis of atrial cardiomyopathy allows outcome prediction following pulmonary vein isolation. Clinical Research in Cardiology, 2021, 110, 1770-1780.	1.5	8
36	Determinants of fibrotic atrial cardiomyopathy in atrial fibrillation. A multicenter observational study of the RETAC (reseau europÃ©en de traÃ®tement dâ€™arrhythmies cardiaques)-group. Clinical Research in Cardiology, 2022, 111, 1018-1027.	1.5	7

#	Article	IF	Citations
37	Left Atrial Hypertension, Electrical Conduction Slowing, and Mechanical Dysfunction â€“ The Pathophysiological Triad in Atrial Fibrillation-Associated Atrial Cardiomyopathy. Frontiers in Physiology, 2021, 12, 670527.	1.3	6
38	Echocardiographic and Electrocardiographic Determinants of Atrial Cardiomyopathy Identify Patients with Atrial Fibrillation at Risk for Left Atrial Thrombogenesis. Journal of Clinical Medicine, 2022, 11, 1332.	1.0	5
39	Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study. Clinical and Translational Science, 2022, 15, 1204-1214.	1.5	4
40	Impact of On-Clopidogrel Platelet Reactivity on Incidence of Peri-Interventional Bleeding in Patients Undergoing Transcatheter Aortic Valve Implantation. Journal of Clinical Medicine, 2022, 11, 2871.	1.0	1